Wednesday, July 8, 2026

Patent intelligence · US

US 12428379

Acylsulfonamide KAT6A inhibitors

granted A61KA61K31/415A61K31/4155A61K31/426
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 19
Applicant portfolio 8
Patent details — US 12428379
Jurisdiction
US
Status
granted
Grant date
Sep 30, 2025
Expiration
Sep 25, 2045
Claims
27
CPC classes
A61K, A61K31/415, A61K31/4155, A61K31/426
View on Google Patents ↗

Quick answer

US 12428379 (Acylsulfonamide KAT6A inhibitors) is held by Olema Pharmaceuticals, Inc.. Status: granted. Granted Sep 30, 2025. Expires Sep 25, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
27
CPC classes
A61K, A61K31/415, A61K31/4155, A61K31/426, A61K31/436, A61K31/4439

More from Olema Pharmaceuticals, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12370181

    Regimens of estrogen receptor antagonists

    Olema Pharmaceuticals, Inc. · Expires Jul 24, 2045

    granted
  2. US 11672785

    Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs

    Olema Pharmaceuticals, Inc. · Expires Jun 8, 2043

    granted
  3. US 11229630

    Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs

    Olema Pharmaceuticals, Inc. · Expires Jan 20, 2042

    granted
  4. US 10624878

    Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs

    Olema Pharmaceuticals, Inc. · Expires Apr 16, 2040

    granted
  5. US 10292971

    Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs

    Olema Pharmaceuticals, Inc. · Expires May 16, 2039

    granted
  6. US 9018244

    Benzopyran compounds, compositions and uses thereof

    Olema Pharmaceuticals, Inc. · Expires Apr 23, 2035

    granted
  7. US 8071545

    Therapies and compositions for controlling the stress mechanism and for stabilizing hemostasis in an organism

    Lewis S. Coleman, MD, Inc. · Expires Dec 1, 2031

    granted

Frequently asked questions

What is US patent 12428379?

US 12428379 (Acylsulfonamide KAT6A inhibitors) is held by Olema Pharmaceuticals, Inc.. Status: granted. Granted Sep 30, 2025. Expires Sep 25, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12428379?

Olema Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8 pharmaceutical patents for this assignee.

When does US 12428379 expire?

Our index shows an expiration date of Sep 25, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.